Anders Thalme

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman, Ola Blennow, Lotta Hansson et al. · EBioMedicine · 2021 · 223 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +10

Prospective Study of Prognostic Factors in Community‐Acquired Bacteremic Pneumococcal Disease in 5 Countries

Mats Kalin, Åke Örtqvist, Manuel Almela et al. · The Journal of Infectious Diseases · 2000 · 183 citations

Veterinary Medicine, Infectious Diseases, Internal Medicine +15

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 135 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17